Tatiana Smirnova

Dr. Tatiana Smirnova

hematology, Centre Hospitalier Universitaire Vaudois - Lausanne, Suisse, Lausanne, Vaud, Switzerland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CSCaroline Spertini
Caroline Spertini
BBBénédicte Baïsse
Bénédicte Baïsse
MBMarta Bellone
Marta Bellone
MGMilica Gikic
Milica Gikic
TSTatiana Smirnova
Tatiana Smirnova
OSOlivier Spertini
Olivier Spertini
Acute myeloid and lymphoblastic leukemia are poor prognosis hematologic malignancies, which disseminate from the bone marrow into the blood. Blast interactions with selectins expressed by vascular endothelium promote the development of drug resistance and leukostasis. While the role of selectins in initiating leukemia blast adhesion is established, our knowledge of the involved selectin ligands is incomplete. Using various primary acute leukemia cells and U937 monoblasts, we identified here functional selectin ligands expressed by myeloblasts and lymphoblasts by performing biochemical studies, expression inhibition by RNA interference and flow adhesion assays on recombinant selectins or selectin ligands immunoadsorbed from primary blast cells. Results demonstrate that P-selectin glycoprotein ligand-1 (PSGL-1) is the major P-selectin ligand on myeloblasts, while it is much less frequently expressed and used by lymphoblasts to interact with endothelial selectins. To roll on E-selectin, myeloblasts use PSGL-1, CD44, and CD43 to various extents and the contribution of these ligands varies strongly among patients. In contrast, the interactions of PSGL-1-deficient lymphoblasts with E-selectin are mainly supported by CD43 and/or CD44. By identifying key selectin ligands expressed by acute leukemia blasts, this study offers novel insight into their involvement in mediating acute leukemia cell adhesion with vascular endothelium and may identify novel therapeutic targets.

28 March 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
CSCaroline Spertini
Caroline Spertini
ABAlexandre P. Bénéchet
Alexandre P. Bénéchet
FBFlora Birch
Flora Birch
ABAxel Bellotti
Axel Bellotti
MRMónica Román-Trufero
Mónica Román-Trufero
TSTatiana Smirnova
Tatiana Smirnova
The malignant microenvironment plays a major role in the development of resistance to therapies and the occurrence of relapses in acute myeloid leukemia (AML). We previously showed that interactions of AML blasts with bone marrow macrophages (MΦ) shift their polarization towards a protumoral (M2-like) phenotype, promoting drug resistance; we demonstrated that inhibiting the colony-stimulating factor-1 receptor (CSF1R) repolarizes MΦ towards an antitumoral (M1-like) phenotype and that other factors may be involved. We investigated here macrophage migration inhibitory factor (MIF) as a target in AML blast survival and protumoral interactions with MΦ. We show that pharmacologically inhibiting MIF secreted by AML blasts results in their apoptosis. However, this effect is abrogated when blasts are co-cultured in close contact with M2-like MΦ. We next demonstrate that pharmacological inhibition of MIF secreted by MΦ, in the presence of granulocyte macrophage-colony stimulating factor (GM-CSF), efficiently reprograms MΦ to an M1-like phenotype that triggers apoptosis of interacting blasts. Furthermore, contact with reprogrammed MΦ relieves blast resistance to venetoclax and midostaurin acquired in contact with CD163+ protumoral MΦ. Using intravital imaging in mice, we also show that treatment with MIF inhibitor 4-IPP and GM-CSF profoundly affects the tumor microenvironment in vivo: it strikingly inhibits tumor vasculature, reduces protumoral MΦ, and slows down leukemia progression. Thus, our data demonstrate that MIF plays a crucial role in AML MΦ M2-like protumoral phenotype that can be reversed by inhibiting its activity and suggest the therapeutic targeting of MIF as an avenue towards improved AML treatment outcomes.

21 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TSTatiana Smirnova
Tatiana Smirnova
CSCaroline Spertini
Caroline Spertini
OSOlivier Spertini
Olivier Spertini
Relapse is a major issue in acute myeloid leukemia (AML) and while the contribution of gene mutations in developing drug resistance is well established, little is known on the role of macrophages (MΦs) in an AML cell microenvironment. We examined whether myeloblasts could educate MΦs to adopt a protumoral orientation supporting myeloblast survival and resistance to therapy. Flow cytometry analyses demonstrated that M2-like CD163+ MΦs are abundantly present, at diagnosis, in the bone marrow of AML patients. We showed that myeloblasts, or their conditioned medium, polarize monocytes to M2-like CD163+ MΦs, induce the secretion of many protumoral factors, and promote myeloblast survival and proliferation as long as close intercellular contacts are maintained. Importantly, pharmacologic inhibition of the CSF1 receptor (CSF1R), in the presence of GM-CSF, reprogrammed MΦ polarization to an M1-like orientation, induced the secretion of soluble factors with antitumoral activities, reduced protumoral agonists, and promoted the apoptosis of myeloblasts interacting with MΦs. Furthermore, myeloblasts, which became resistant to venetoclax or midostaurin during their interplay with protumoral CD163+ MΦs, regained sensitivity to these targeted therapies following CSF1R inhibition in the presence of GM-CSF. These data reveal a crucial role of CD163+ MΦ interactions with myeloblasts that promote myeloblast survival and identify CSF1R inhibition as a novel target for AML therapy.

26 August 2026 in Nature Aging
Verified
Journal Article
Open access
PDF file
EREnrique Gabandé Rodríguez
Enrique Gabandé Rodríguez
GSGonzalo Soto-Heredero
Gonzalo Soto-Heredero
Elisa CarrascoElisa Carrasco
Elisa Carrasco
CACarlos Anerillas
Carlos Anerillas
JEJosé Ignacio Escrig-Larena
José Ignacio Escrig-Larena
MMMaria Mittelbrunn
Maria Mittelbrunn
Age-associated hematopoietic skewing results in an increase in the neutrophil-to-lymphocyte ratio, which serves as a strong predictor of all-cause mortality in older adults, although its causes are incompletely understood. Here we show that cytotoxic CD4 + T lymphocytes accumulate in the bone marrow of mice during aging and induce myelopoiesis, increasing the neutrophil-to-lymphocyte ratio. T cell receptor-dependent induction of mitochondrial stress and activation of STING upregulates the chemokine CCL5 in CD4 + T lymphocytes. During aging, hematopoietic stem cells and downstream myeloid progenitors upregulate CCR5, the primary receptor for CCL5. Genetic ablation of Ccr5 in hematopoietic progenitors mitigates T cell-induced myeloid skewing and neutrophil expansion. Pharmacological blockade of CCR5 using the Food and Drug Administration-approved drug maraviroc normalizes myelopoiesis, reduces circulating and tissue-infiltrating neutrophils, and improves multiple aging-related biomarkers and functional outcomes in aged mice. Together, these findings demonstrate a T cell–bone marrow axis that exacerbates age-associated decline and highlight CCR5 inhibition as a potential geroprotective strategy.

1 January 2023 in Medicina i vysokie tehnologii
Verified
Journal Article
Closed access
NRNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian
National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian
TSTatiana Smirnova
Tatiana Smirnova
MZM.V. Zubasheva
M.V. Zubasheva
NSN.V. Shevlyagina
N.V. Shevlyagina
AAA.I. Akhmetova
A.I. Akhmetova
IYI.V. Yaminsky
I.V. Yaminsky
The article presents data on the sporulation process of Brevibacillus laterosporus, which are of interest due to their biological activity. Crystalline and acrystalline strains of Brevibacillus laterosporus have insecticidal properties.

23 February 2022 in Кардиология в Беларуси
Verified
Journal Article
Open access
ВСВ.а. Снежицкий
В.а. Снежицкий
МКМ.н. Курбат
М.н. Курбат
ИКИ.а. Карпуть
И.а. Карпуть
АРА.ю. Рубинский
А.ю. Рубинский
ЕЕЕ.а. Евстрат
Е.а. Евстрат
TSTatiana Smirnova
Tatiana Smirnova